{"id":9,"date":"2016-11-01T15:39:26","date_gmt":"2016-11-01T15:39:26","guid":{"rendered":"https:\/\/dynasci.com\/?page_id=9"},"modified":"2021-01-27T07:10:06","modified_gmt":"2021-01-27T07:10:06","slug":"about","status":"publish","type":"page","link":"https:\/\/dynasci.com\/?page_id=9","title":{"rendered":"About"},"content":{"rendered":"

About DynaSci<\/h2>\n<\/div>
<\/div>
<\/div><\/div>
<\/div>
  • <\/i><\/span>
    \n

    DynaSci’s founders have been actively involved in the pharmaceutical industry since 1923 – a generational affair, each succession has built on the collective experience of their predecessors, to further develop their understanding of the sector.<\/p>\n<\/div><\/li>

  • <\/i><\/span>
    \n

    Following the successful sale of MN Pharmaceuticals to Amgen in 2012, a series of carve-outs laid the building blocks of what was to become DynaSci. The Family still retains assets in some of the oldest industrial sectors in Turkey.<\/p>\n<\/div><\/li>

  • <\/i><\/span>
    \n

    DynaSci is made up of seasoned managers both from within, and out of the Pharmaceutical Industry. The new operating model is based on the shortcomings of a conventional industry, creating a re-invented healthcare company.<\/p>\n<\/div><\/li>

  • <\/i><\/span>
    \n

    DynaSci creates; easy to manufacture, patent protected, pre-mix formulations, with clinical studies, focused on products and indications with a large global potential.<\/p>\n<\/div><\/li><\/ul>

    <\/div>
    <\/div>
    <\/div>
    <\/div><\/div><\/div>
    <\/div><\/div><\/div><\/div><\/div>

    Team<\/strong><\/h2>\n<\/div>
    <\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"M.<\/div><\/div>
    M. Levent Selamoglu<\/span>Chairman<\/span><\/div><\/div>
    Mr. Levent is a pharmaceutical veteran with more than 25 years of pharma industry experience across Central & Eastern Europe and Middle East & North Africa. Levent was the previous CEO and Chairman of Mustafa Nevzat Pharma (\u201cMN Pharma\u201d), the leading injectable generics pharmaceutical company in CEE. MN Pharma was the first and only company to receive US FDA approval in Turkey and was responsible for the launch and commercialisation of the first biosimilar product in Turkey. MN Pharma was sold to Amgen, one of the world\u2019s largest biotechnology companies, for $700m in 2012. At the time of sale, MN Pharma was fully integrated (including API production), employed 1,200 people and generated approximately $200m in annual revenue. Levent is a non-executive Board Member of Phamactive (generic pharma), Imuneks Pharma (OTC) and Polus Global (Korean biosimilar company). Levent was also recently a senior advisor to Polpharma and currently leads Frontier Pharma\u2019s advisory board.<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Mehmet<\/div><\/div>
    Mehmet N. Pisak<\/span>CEO<\/span><\/div><\/div>
    Mehmet Pisak has deep experience in leading and managing a large pharma business and has assembled a skilled and motivated team to execute the DynaSci vision\/strategy alongside him. With a successful exit to his name, he is also well-placed to understand the needs of investors and the evolution of the market. Mr. Pisak has been involved in all aspects of the industry; he has patented several new treatment modalities and has overseen the development and commercialization of more than 30 products ranging from oral to injectable, OTC to Rx . Additionally, he has also realized multiple in-licensing and out-licensing deals, including the out-licensing and sale of a regional blockbuster to a big Pharma company. Furthermore, he has also supervised the construction of an injectable oncolytics plant, including all technical procurement, as a Greenfield project (FDA approved). Finally, he was heavily involved with the sale of MN Pharmaceuticals to Amgen at a record setting 17X EBIDTA multiplier. His past and present experience makes him very well placed to repeat his success with DynaSci, for which he has personally invested 8,5 million USD to reach this stage of the development cycle. <\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Dr.<\/div><\/div>
    Dr. Cem Aydogan<\/span>CSO<\/span><\/div><\/div>
    Dr. Aydogan holds a Ph.D. and M.D. from the University of Cologne, Germany with a special emphasis on glycoproteins and immunology. With over two decades of experience in the pharmaceutical and nutrition industries, Dr. Aydogan combines a unique experience of being a scientist, a physician and management professional. After receiving his degrees, Dr. Aydogan practiced as physician in the department of Endocrinology at the Faculty of Medicine in Cologne. Since then, Dr. Aydogan has held management positions in the pharmaceutical and nutrition industries, with companies like Johnson&Johnson, and Frutarom\/ICC Industries. He is the founder of Bluestone Pharma, a company supplying special pro-biotics for special indications, Nouvellune GmbH, a company supplying novel innovative supplements globally and is currently the CEO of PhytoNet AG, a Swiss-based company providing international consulting and business development\/sales services in the pharmaceutical, OTC and dietary supplement industries.<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Can<\/div><\/div>
    Can Duna<\/span>CIO<\/span><\/div><\/div>
    Mr. Can Duna has 16 years of Emerging Markets sales & advisory experience across varied products (ranging from VC, PE to M&A, but also Government and Policy Affairs, to general Management and Financial advisory) having worked at Garanti Bank International, Lehman Brothers and as a Managing Partner at AB Consultancy. He is a graduate of the Lyc\u00e9e Fran\u00e7ais Pierre Loti and received his BS from Brown University in 2003<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Hakan<\/div><\/div>
    Hakan Ansen<\/span>CFO<\/span><\/div><\/div>
    Mr. Hakan Ansen has 19 years of Emerging Markets sales & structuring experience across Global Markets products (capital markets, client financing, credit, rates, foreign exchange, local markets and commodities) having worked for Bankers Trust A.S., Lehman Brothers International (Europe), Deutsche Bank AG London, Standard Bank Plc and Unlu & Co. during his career. He is a graduate of Robert College and received his BS from Massachusetts Institute of Technology in 1995 and his MBA from Columbia Business School in 1999<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Yalcin<\/div><\/div>
    Yalcin Sisa<\/span>CMO<\/span><\/div><\/div>
    Mr. Yal\u00e7\u0131n Sisa has 15 years of marketing and communications experience both in off and online media channels. He previously worked for Stroer, one of the leading Out of Home Media Company\u2019s, and was responsible for further developing sales, and, creating new and alternative sales channels. Previously to that, he worked in Turkey\u2019s leading outdoor production company CIPS Production as a sales and operations director. Worked with Reckitt Benckiser, Netflix, Vodafone and Coca \u2013Cola. Recently, he founded a media purchasing agency, Mediatic, acting both for digital and offline marketing activities in 2011. <\/div><\/div><\/div>
    <\/div><\/div><\/div>

    Advisory Board<\/strong><\/h2>\n<\/div>
    <\/div><\/div><\/div>
    \"Samir<\/div><\/div>
    Samir Abhyankar<\/span><\/span><\/div><\/div>
    Samir Abhyankar is a Private Equity professional with 20 years\u2019 experience. He was a Partner at TPG Growth($8BN AuM) and TPG Rise Fund ($2.0 BN Impact Fund) \u00a0based in London, where he worked across sectors covering the group’s investment activities in Africa. \u2013 He helped set up TPG\u2019s activities in Africa. Focus sectors included Social Infrastructure, Financial Services, Food and Agriculture. Prior to joining the firm in 2015, Samir was a Partner at Satya Capital and a Vice President at Citi Venture Capital International. Samir graduated with an MBA from INSEAD and holds an MA from John’s Hopkins’ School of Advanced International Studies.<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Kiren<\/div><\/div>
    Kiren Naidoo<\/span><\/span><\/div><\/div>
    Kiren is a former pharmaceutical industry-focused investment banker, most recently a senior Vice President at Bank of America Merrill Lynch in Johannesburg and London. Kiren\u2019s expertise spans strategic and financial advisory (covering mergers & acquisitions and business development) and capital raising activities (across debt, equity and hybrid products). Kiren\u2019s pharma expertise covers branded generics, specialty pharma and consumer health. Some of Kiren\u2019s most notable transactions include: Sale of MN Pharma to Amgen ($700m), Sale of Bedford Laboratories (owned by Boehringer Ingelheim) to Hikma ($300m), Swap of Boehringer Ingelheim\u2019s Consumer Healthcare Business with Sanofi\u2019s Animal Health Business (Merial) (\u20ac22bn) and the Financing of Teva\u2019s $40.5bn acquisition of Allergan Generics (Actavis). Kiren also leads Frontier Pharma\u2019s advisory activities in Central and Eastern Europe, Russia \/ CIS, Middle East \/ North Africa, sub-Saharan Africa and Central America.<\/div><\/div><\/div>
    <\/div><\/div><\/div>
    \"Omer<\/div><\/div>
    Omer Cem Selamoglu<\/span><\/span><\/div><\/div>
    \u00d6mer graduated from Bilgi university Law School in 2010 and completed Bussines Law LLM at UC Berkeley School of Law in 2015. He supports domestic and international clients with
    \ncorporate counseling matters related to their daily business. His work includes drafting, revision and negotiation of contracts such as share purchase and shareholders agreements, distributorship and so forth.\u00a0\u00d6mer prepares tailor made legal memorandums on subjects requested by clients with a special interest on e-commerce. He maintains an active arbitration and litigation practice and specializes on goodwill (portfolio) compensation along with disputes arising out of international carriage of goods. \u00d6mer is also a sworn translator in English and Italian languages.
    \n\u00d6mer also acts as a Mediator registered to Mediator\u2019s Registr<\/div><\/div><\/div>
    <\/div><\/div><\/div><\/div><\/div>